Company news

Jazz Pharmaceuticals plc news in 2021

Jazz Pharmaceuticals plc's news releases, calls and decks from 2021, newest first.

View company

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder

December 29, 2021

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

December 14, 2021

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

December 12, 2021

Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting

December 11, 2021

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting

November 30, 2021

Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer

November 29, 2021

Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance

November 8, 2021

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting

November 3, 2021

Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021

October 25, 2021

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

September 12, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

August 11, 2021

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

August 9, 2021

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

August 2, 2021

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

July 21, 2021

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021

July 19, 2021

Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021

July 12, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

June 29, 2021

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

June 24, 2021

Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc

June 16, 2021

Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community

June 13, 2021

Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021

June 8, 2021

Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021

May 25, 2021

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

May 19, 2021

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

May 4, 2021

Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021

May 3, 2021

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results

May 3, 2021

Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering

April 28, 2021

GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

April 22, 2021

Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering

April 21, 2021

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes

April 19, 2021

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

April 18, 2021

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia

April 11, 2021

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

March 29, 2021

Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum

March 21, 2021

Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia

March 17, 2021

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

February 22, 2021

Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

February 15, 2021

Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021

February 8, 2021

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 2, 2021

Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Calls in 2021

Decks in 2021